Investor Presentation 3 rd Qtr. - FY 2018

Transcription

1 Investor Presentation 3 rd Qtr. - FY th January, of 34

2 Content Content INDIA 1 India 2 Global 3 Infrastructure 4 Financial Highlights 5 Recognition 2 of 34

3 INDIA 1 India 3 of 34

4 India Branded Generics INDIA India Therapeutic Segments Team & Products Differentiation Cardiology Ophthalmology Dermatology Pain Management 15 Divisions 3,000+ MRs 270+ Products About 60% products First-to-Market Sizeable chronic portfolio Consistent Innovation Leadership in sub therapeutic segments 4 of 34

5 India Sales INDIA India India Branded Sales 1 - Q3 (Rs. cr.) 200 4% Pain 6% Ophthalmology 30% India Branded Sales 1-9M (Rs. cr.) % Therapeutic Break-up IMS MAT December Q3 FY 2017 Q3 FY 2018 Total India Sales 2 - Q3 (Rs. cr.) 200 4% Cardiology 41% Pain 6% Dermatology 23% Ophthalmology 28% 0 9M FY M FY 2018 Total India Sales 2-9M (Rs. cr.) 1% Q3 FY 2017 Q3 FY 2018 Source: Company Cardiology 40% Therapeutic Break-up IMS MAT December 2016 Dermatology 26% M FY M FY 2018 Source: Company 1 = excluding institution 2 = including institution 5 of 34

6 Faster than Industry - IPM India 40% 36% 30% 29% 26% 23% 20% 10% 10% 10% 12% 14% 9% 5% 0% Mar-2014 Mar-2015 Mar-2016 Mar-2017 Dec-2017 IPM = Indian Pharmaceutical Market Source: IMS MAT IPM Ajanta Pharma 6 of 34

7 Within Segments Ajanta Way Ahead India 18% 16% 17% 16% 14% 13% 12% 10% 9% 9% 9% 8% 6% 5% 6% 4% 3% 2% 0% -2% Pharma Market Cardiology Ophthalmology Pain Mgt. Dermatology -1% IPM Ajanta Pharma IPM = Indian Pharmaceutical Market Source: IMS MAT December of 34

8 IPM - Ranking India Rank Dec 2017 Dec 2016 Mar 2005 Ophthal Derma Cardio Pain NA Ajanta IPM = Indian Pharmaceutical Market Source: IMS 8 of 34

9 2 Global 9 of 34

10 Global Presence Global USA West Asia (3 Countries) CIS (6 Countries) South East Asia (3 Countries) India Africa (19 Countries) 10 of 34

11 USA Global ANDA Status Approval : Final 20 (1 in Q3), Tentative - 2 Under approval : 16 (Filed 1 in Q3) Filing target FY 2018 : ~10-12 (Filed 6 in 9M) Sales & Marketing 17 Products commercialized (2 in Q3) Price erosion slowing down Gaining market share with better execution 11 of 34

12 Africa Global Products Product Registrations 1,359 Segments - Anti Malaria, Multivitamin, Cardio, Antibiotic, Gynaec, MED, Pain Sales & Marketing Branded business post healthy growth Africa 19 countries Institution business shrinks impacting overall Africa growth Expanding market presence with new launches & team addition 12 of 34

13 Asia Global Products Product Registration CIS (6 countries) Segments Cardio, Pain, GI, Diabetes, Antibiotic, Derma, Anti Histamine WEST ASIA (3 countries) Asia 12 countries SOUTH EAST ASIA (3 countries) Sales & Marketing Enhanced focus showing results Increased thrust with product addition Currency situation improving in the region 13 of 34

14 Export Sales Q3 (Consolidated) Global Regional Break-up (Rs. cr.) Total Exports (Rs. cr.) % (14%) % % % 1 3 Africa Asia USA Others Q3 FY 2017 Q3 FY 2018 Rs. cr. 0 Q3 FY 2017 Q3 FY 2018 Q3 FY 2017 Q3 FY 2018 Gth Africa (14%) Asia % Source: Company USA % Others % Total % 14 of 34

15 Export Sales 9M (Consolidated) Global Regional Break-up (Rs. cr.) Total Exports (Rs. cr.) % 1,086 1, (2%) % % % 3 6 Africa Asia USA Others 9M FY M FY 2018 Rs. cr. 0 9M FY M FY M FY M FY 2018 Gth Africa (2%) Asia % Source: Company USA % Others % Total 1,002 1,086 8% 15 of 34

16 Total Consolidated Sales Global Q3 Revenue Break-up (Rs. cr.) 9M Revenue Break-up (Rs. cr.) 12% 6% % % , % % 1, India Exports Total Revenue 0 India Exports Total Revenue Q3 FY 2017 Q3 FY M FY M FY 2018 Q3 FY 2017 Q3 FY 2018 Rs. cr. Gth India % 9M FY M FY 2018 Rs. cr. Gth India % Exports % Total Revenue % Exports 1,002 1,086 8% Total Revenue 1,476 1,567 6% 16 of 34

17 INDIA 3 Infrastructure 17 of 34

18 Prepared for next growth Infrastructure Formulation Manufacturing 3 existing facilities in Aurangabad, Maharashtra (1 USFDA & WHO Pre-Q approved) New US FDA approved facility in Dahej (Gujarat) New facility in Guwahati (Assam), 2 nd phase under implementation 1 Facility at Mauritius API Manufacturing 1 Facility at Waluj (Aurangabad) - Captive Consumption API Plant - Waluj Paithan Plant Dahej Plant 18 of 34

19 R&D Thrust Infrastructure R&D spend & % of Oper. Income (Excluding Capex) Rs. cr % % 6% % % FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 Adding Spend - Q3 FY Rs. 43 cr. (7%), 9M FY Rs.138 cr. (9%) New Building nearing completion Total Team 850+ Scientists 19 of 34

20 INDIA 4 Financial Highlights 20 of 34

21 P&L Synopsis Q3 FY 2018 (Consolidated) Financials Rs. cr. Q3 FY 2018 % Q3 FY 2017 % % Growth Exports % % 15% Domestic % % 4% Other Op. Income 12 2% 18 3% (33%) Income from Operations % EBITDA % % 15% PBT % % 9% PAT % % 3% Total Comprehensive Income % % 4% 21 of 34

22 P&L Synopsis 9M FY 2018 (Consolidated) Financials Rs. cr. 9M FY 2018 % 9M FY 2017 % % Growth Exports 1,086 68% 1,002 66% 8% Domestic % % 1% Other Op. Income 33 2% 48 3% (31%) Income from Operations 1,601 1,525 5% EBITDA % % (1%) PBT % % (2%) PAT % % (5%) Total Comprehensive Income % % (4%) 22 of 34

23 Detailed P&L Q3 FY 2018 (Consolidated) Financials Rs. cr. FY 2018 FY 2017 Income from Operations Other Income 15 2% 19 3% Total Income Materials consumed % % Employee Benefit 95 16% 77 14% Finance Cost 0 0% 0 0% Depreciation 15 2% 15 3% Other Expenses % % Total expenses % % Profit before tax % % Tax Expense 50 8% 38 7% Net Profit % % Other Comprehensive Income (1) (1) Q3 Total Comprehensive Income % % 23 of 34

24 Detailed P&L 9M FY 2018 (Consolidated) Financials 9M Rs. cr. FY 2018 FY 2017 Income from Operations 1,601 1,525 Other Income 20 1% 21 1% Total Income 1,621 1,546 Materials consumed % % Employee Benefit % % Finance Cost 0 0% 1 0% Depreciation 43 3% 42 3% Other Expenses % % Total expenses 1,126 69% 1,042 67% Profit before tax % % Tax Expense 120 7% 111 7% Net Profit % % Other Comprehensive Income 3 (2) Total Comprehensive Income % % 24 of 34

25 Consistent Track Record (Consolidated) Financials Consolidated Total Income (Rs. cr.) PAT (Rs. cr.) & PAT Margin (%) 12% 19% 21% 24% 25% 1,502 1,771 2, , of 34

26 Consistent Track Record (Consolidated) Financials EBITDA Margin (%) 24% 31% 34% 34% 35% Net Margin (%) 19% 21% 24% 25% 12% RONW (%) 32% 47% 43% 40% 37% ROCE (%) 37% 45% 50% 44% 41% of 34

27 Consistent Track Record (Consolidated) Financials EPS (Rs.) 58 Dividend per share (Rs.) (FV Rs. 2/-) Dividend Payout (%) 25% Book Value per share (Rs.) % 18% 19% 18% of 34

28 Consistent Track Record (Consolidated) Financials 0.32 Total Debt / Equity (Ratio) Receivable Days (Nos.) Inventory Days (Nos.) 134 Payable Days (Nos.) of 34

29 INDIA 5 Recognition 29 of 34

30 Forbes India Leadership Award 2017 Recognition Nominated Mr. Yogesh & Rajesh Agrawal (MD & Jt. MD) Nominated for Next Generation Entrepreneur of the year under Forbes Leadership Award of 34

31 Improved Ranking Recognition Publication Sales Rank Profit Rank Business Today Business India Business Standard Business World Economic Times Fortune of 34

32 Fastest Wealth Creator Recognition Ajanta Pharma Listed as Fastest Wealth Creator for the 3 rd year in a row by Motilal Oswal (Dec 2017) 32 of 34

33 For updates and company information please visit our website: Thank You For specific queries, contact: Rajeev Agarwal Ajanta Pharma Limited Ajanta House, Charkop, Kandivli (W), Mumbai CIN No. - L24230MH1979PLC of 34

34 Disclaimer This presentation may include certain forward looking statements, based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. The Company disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. This material is used during oral presentation; it is not a complete record of the discussion. 34 of 34